Antibody-RNA Conjugates represent a significant advancement in the treatment of challenging and rare diseases with unmet medical need.

miRecule, a biotechnology company developing RNA therapies, and GBI Biomanufacturing, a CDMO, entered a strategic partnership to advance the development and clinical supply of miRecule’s Antibody-RNA ...

While the access to combination treatments problem is nothing new, its sheer magnitude means it has, to date, gone unsolved. But now, an initiative spearheaded by Takeda is starting to shift the dial.